These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 34159217)

  • 1. The Relationship Between Hepatitis C Virus Rates and Office-Based Buprenorphine Access in Ohio.
    Brook DL; Hetrick AT; Chettri SR; Schalkoff CA; Sibley AL; Lancaster KE; Go VF; Miller WC; Kline DM
    Open Forum Infect Dis; 2021 Jun; 8(6):ofab242. PubMed ID: 34159217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Descriptive Study on Opioid Misuse Prevalence and Office-Based Buprenorphine Access in Ohio Prior to the Removal of the Drug Addiction Treatment Act of 2000 Waiver.
    McKnight ER; Dong Q; Brook DL; Hepler SA; Kline DM; Bonny AE
    Cureus; 2023 Mar; 15(3):e36903. PubMed ID: 37139287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C Virus Testing and Treatment Among Persons Receiving Buprenorphine in an Office-Based Program for Opioid Use Disorders.
    Carey KJ; Huang W; Linas BP; Tsui JI
    J Subst Abuse Treat; 2016 Jul; 66():54-9. PubMed ID: 26988423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
    Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
    Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. County-level neonatal opioid withdrawal syndrome rates and real-world access to buprenorphine during pregnancy: An audit ("secret shopper") study in Missouri.
    Bedrick BS; Cary C; O'Donnell C; Marx C; Friedman H; Carter EB; Raghuraman N; Stout MJ; Ku BS; Xu KY; Kelly JC
    Drug Alcohol Depend Rep; 2024 Mar; 10():100218. PubMed ID: 38380272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. County-Level Vulnerability Assessment for Rapid Dissemination of HIV or HCV Infections Among Persons Who Inject Drugs, United States.
    Van Handel MM; Rose CE; Hallisey EJ; Kolling JL; Zibbell JE; Lewis B; Bohm MK; Jones CM; Flanagan BE; Siddiqi AE; Iqbal K; Dent AL; Mermin JH; McCray E; Ward JW; Brooks JT
    J Acquir Immune Defic Syndr; 2016 Nov; 73(3):323-331. PubMed ID: 27763996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio.
    Molfenter T; Sherbeck C; Zehner M; Quanbeck A; McCarty D; Kim JS; Starr S
    Subst Abuse Treat Prev Policy; 2015 Mar; 10():13. PubMed ID: 25884206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buprenorphine Prescribing Availability in a Sample of Ohio Specialty Treatment Organizations.
    Molfenter T; Sherbeck C; Zehner M; Starr S
    J Addict Behav Ther Rehabil; 2015; 4(2):. PubMed ID: 26380328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees.
    Wen H; Hockenberry JM; Pollack HA
    JAMA Netw Open; 2018 Sep; 1(5):e182943. PubMed ID: 30646185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users.
    Tsui JI; Evans JL; Lum PJ; Hahn JA; Page K
    JAMA Intern Med; 2014 Dec; 174(12):1974-81. PubMed ID: 25347412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioid Prescribing Rates in Nonmetropolitan and Metropolitan Counties Among Primary Care Providers Using an Electronic Health Record System - United States, 2014-2017.
    García MC; Heilig CM; Lee SH; Faul M; Guy G; Iademarco MF; Hempstead K; Raymond D; Gray J
    MMWR Morb Mortal Wkly Rep; 2019 Jan; 68(2):25-30. PubMed ID: 30653483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming Barriers to Prescribing Buprenorphine for the Treatment of Opioid Use Disorder: Recommendations from Rural Physicians.
    Andrilla CHA; Moore TE; Patterson DG
    J Rural Health; 2019 Jan; 35(1):113-121. PubMed ID: 30339720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Barriers Rural Physicians Face Prescribing Buprenorphine for Opioid Use Disorder.
    Andrilla CHA; Coulthard C; Larson EH
    Ann Fam Med; 2017 Jul; 15(4):359-362. PubMed ID: 28694273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacy-related buprenorphine access barriers: An audit of pharmacies in counties with a high opioid overdose burden.
    Kazerouni NJ; Irwin AN; Levander XA; Geddes J; Johnston K; Gostanian CJ; Mayfield BS; Montgomery BT; Graalum DC; Hartung DM
    Drug Alcohol Depend; 2021 Jul; 224():108729. PubMed ID: 33932744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in U.S. office-based practices.
    Andraka-Christou B; Capone MJ
    Int J Drug Policy; 2018 Apr; 54():9-17. PubMed ID: 29324253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Access to and Payment for Office-Based Buprenorphine Treatment in Ohio.
    Parran TV; Muller JZ; Chernyak E; Adelman C; Delos Reyes CM; Rowland D; Kolganov M
    Subst Abuse; 2017; 11():1178221817699247. PubMed ID: 28642642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retention in buprenorphine treatment is associated with improved HCV care outcomes.
    Norton BL; Beitin A; Glenn M; DeLuca J; Litwin AH; Cunningham CO
    J Subst Abuse Treat; 2017 Apr; 75():38-42. PubMed ID: 28237052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. U.S. trends in the supply of providers with a waiver to prescribe buprenorphine for opioid use disorder in 2016 and 2018.
    Ghertner R
    Drug Alcohol Depend; 2019 Nov; 204():107527. PubMed ID: 31525570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications of Increased Access to Buprenorphine for Medical Providers in Rural Areas: A Review of the Literature and Future Directions.
    Gregory HM; Hill VM; Parker RW
    Cureus; 2021 Nov; 13(11):e19870. PubMed ID: 34976492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties.
    Stein BD; Pacula RL; Gordon AJ; Burns RM; Leslie DL; Sorbero MJ; Bauhoff S; Mandell TW; Dick AW
    Milbank Q; 2015 Sep; 93(3):561-83. PubMed ID: 26350930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.